Press releases

Press releases

 

Genomatix Pathway System (GePS) now available in Illumina's BaseSpace Apps.

GePS brings pathway analysis to BaseSpace.

 

Munich, Germany, September 11, 2013 - Genomatix today announced it has added the Genomatix Pathway System (GePS) to BaseSpace Apps, Illumina’s dedicated applications store and informatics community dedicated to advancing genomic analysis.

 

Using GePS, researchers can generate and visualize genetic networks and pathways and easily access a multitude of data on the genes and gene-gene connections they consist of. Combined with expression level data generated through next-generation sequencing (NGS) experiments, GePS helps scientists identify the key players within biological processes at a functional level.

 

Klaus May, CEO of Genomatix, says: "We're happy to add our technology to Illumina's portfolio of BaseSpace applications. Scientists can now overlay NGS results with the knowledge and data provided by the Genomatix Pathway System. Distributing our software via the cloud infrastructure of BaseSpace will not only enable users to seamlessly access their data, it also makes it possible for us to offer our software at a very competitive price."

 

The Genomatix Pathway System enables researchers to see the biology behind their data by combining NGS results with multiple levels of existing knowledge. Associations with signal transduction pathways, molecular functions, biological processes, tissues, diseases, small molecules and co-cited genes and transcription factors deliver the insight needed to understand the functional context of Omics data. Networks between genes, transcription factors, small molecules and diseases can be generated on various levels and the underlying data is always just one mouse-click away for deeper inspection. The intuitive visualization of expression level values from various conditions or time points combined with data like methylation or histone modification truly gives users the "big picture" without losing any details.

 

Informatics solutions available through BaseSpace Apps allow customers to utilize the tools from a growing community of academic, commercial, and open source providers.

 

About Genomatix:

Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a corporate presence in Ann Arbor, MI (USA), and representatives in California (US), Paris (France), Madrid (Spain), and a distributor (CTC) in Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix' award-winning tools and databases.

 

For further information please contact Genomatix:
Email: info@genomatix.de
Phone: +49 89 599 766 0
http://www.genomatix.com

 


 

CeGaT and Genomatix finalists of Boston Children's Hospital's CLARITY challenge.

Free exomes project for six families and new variant analysis software

San Francisco, Tuebingen, Munich, November 7, 2012 - CeGaT (Center for Genomics and Transcriptomics) GmbH, the Department of Prostate Cancer Research, Institute of Pathology, University Hospital Bonn and Genomatix Software GmbH were announced as finalist (Top 3) of the CLARITY challenge, organized by Boston Children's Hospital. The challenge was started in April 2012 by sending out raw genome sequence data and medical records of three families (children and their immediate relatives) to 30 teams worldwide including BGI, NIH and other well-known genome centers. Two of the patients had undiagnosed neuromuscular diseases, the other a cardiovascular disorder. In all cases current diagnostic tests gave negative results. The aim of the CLARITY Challenge was not only to solve the three cases but also to standardize methods for analyzing, interpreting, reporting and, ultimately, using genomic information in a clinical setting [http://genes.childrenshospital.org]. To achieve this, CeGaT and Genomatix Software successfully combined their expertise and services to solve the cases in time and to identify best methods and practices to provide meaningful results to medical doctors, patients and their families. The team was the only one to correctly flag every likely genetic mutation in all three families.

 

Saskia Biskup, Managing Director of CeGaT says: "I would like to take the opportunity to thank the organizers and sponsors for setting up the CLARITY Challenge. It is a fantastic way to motivate and improve the necessary interaction between researchers and clinicians in order to bring next-generation sequencing to the "next" level. We are delighted that we have been selected as a finalist from the thirty competing teams. We were able to provide useful information for the three families, where the underlying genetic defect could be identified for the first time. In addition this gave us the opportunity to test CeGaT's interdisciplinary approach and know-how in the areas of technology, bioinformatics, biology, and medicine in a competitive setting. The CLARITY challenge is reassuring us that our interdisciplinary approach is the future of diagnostics."

 

CeGaT and Genomatix will now offer their complete genetic analysis service to another six families (six trios or 18 exomes) for free. The families will be selected on the basis of clinical manifestations with a yet unknown genetic cause. This free exomes project will build on the experiences gained in the CLARITY challenge and hopefully allow patients to find better treatment options by understanding the cause of their diseases. Its goal is to follow the CLARITY mission to improve the clinical relevance of genetic analysis in hospitals. Hospitals and doctors who are interested to register patients for this project will find more information on the CeGaT website (www.cegat.de) starting from November 07, 2012.

 

Genomatix today announced the pre-release of GeneGrid, a web application designed to help medical researchers identifying pathogenic genomic variations in humans. The GeneGrid technology allows to annotate and filter thousands of genomic variations within seconds and is supported by a large body of medical and genomics data. In addition, GeneGrid is integrated with many established Genomatix tools like the Genomatix Pathway System (GePS) and the Genomatix Genome Browser. Prior to its official release, GeneGrid was successfully used in the CLARITY challenge. To learn more or analyze your data in GeneGrid, please contact us at: info@genomatix.de.

 

"With GeneGrid we enable medical researchers to find novel and known variants that are medically relevant. We knew that geneGrid was based on a solid technology, but applying it in the CLARITY challenge showed us how powerful it really is in a clinical setting." says Jochen Supper, Head of Computational Biology at Genomatix.

 

About CeGaT:

 

CeGaT, Center for Genomics and Transcriptomics, is a service provider for DNA and RNA sequencing and also offers extensive bioinformatic analyses as well as medical interpretation of data. CeGaT is a worldwide pioneer in applying next-generation sequencing in human genetic diagnostic testing and has developed numerous diagnostic panels. These diagnostic panels enable parallel sequencing and interpretation of all genes associated with a certain disease and hence the probability to confirm a diagnosis is significantly higher. The referring clinicians are provided with a thorough medical report in a very short period of time. CeGaT laboratory is accredited as a molecular human genetic diagnostics laboratory according to DIN EN ISO 15189:2007 and regularly participates in external quality control assessments from the EMQN or German society of human genetics. CeGaT was awarded "Best German Start-Up Company 2011".

 

For further information please contact CeGaT:

Email: info@cegat.de
Phone: +49 7071 565 44 00
http://www.cegat.de

 

About Genomatix:

 

Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (USA), Paris (France), London (UK) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix' award-winning tools and databases.

 

For further information please contact Genomatix:

Email: info@genomatix.de
Phone: +49 89 599 766 0
http://www.genomatix.com

 


 

Genomatix wins the "INDUSTRIEPREIS 2012" in the biotech category at Hannover Messe.

The Genomatix Genome Analyzer has been chosen by a panel of 30 experts to be awarded at the trade show.

Munich, Germany, April 27th, 2012 - Genomatix is proud to announce that it has been awarded the "INDUSTRIEPREIS 2012" in the biotech category at Hannover Messe, the world's biggest technology trade show. The INDUSTRIEPREIS is awarded in 14 categories to companies for products of a high technological, economic, ecological or social value. Nominees and winners are chosen by a panel of 30 experts including professors and specialized journalists. Genomatix has received the INDUSTRIEPREIS for its data analysis and interpretation platform Genomatix Genome Analyzer (GGA).

 

"We're really proud to have received this award for a data analysis solution", says Dr. Korbinian Grote, product manager at Genomatix. "Usually the focus on big technology fairs is more on lab equipment providers, in our field the sequencer manufacturers stand out with ever new records of gigabases of DNA data they can produce. But researchers also need solutions to analyze and interpret these data to extract the information from it and generate new biomedical knowledge." "Being appreciated for our data analysis solutions is certainly a big motivation for the whole team to come up with even more innovative ideas on how to deal with the increasing deluge of Next Generation Sequencing data", adds Dr. Martin Seifert, CEO of Genomatix, "getting an award that explicitly rewards products of technological and social value underlines that NGS is quickly moving from a research tool into the broader field of clinical application."

 

About INDUSTRIEPREIS:
The INDUSTRIEPREIS has been created in 2006 by Huber Verlag für Neue Medien GmbH. It is awarded to companies showing high technological, economical, ecological or social value. It is awarded for a distinct solution or product, which each company needs to present in the application. An independent jury of 30 professionals (including professors and specialized journalists) evaluates the applications and selects category and overall winners.

For more information please visit www.industriepreis.de

 

About Genomatix:
Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (USA), Paris (France), London (UK) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.de

 

For further information please contact:

Genomatix
Dr. Korbinian Grote
Email: grote@genomatix.de
Phone: +49 89 599 766 0

 


 

Genomatix to partner in €30M European epigenomics consortium.

Genomatix will provide data analysis and develop visualization interfaces for the recently started BLUEPRINT project.

 

München, Germany, 17 October 2011 - Genomatix is among the 41 partners of the BLUEPRINT epigenome consortium funded by the European Commission as a high impact project within its seventh framework program (FP7).

 

Genomatix' contributions will be next generation sequencing data analysis and the development of an intuitive GUI to make the project's results easily accessible to researchers within and outside the consortium.

 

"To be part of, and get substantial funding of this ambitious project, is a pleasant affirmation of our research and development efforts to provide high quality data analysis in a very usable way for biologists", says Dr. Martin Seifert, CEO of Genomatix. "We highly appreciate the European Commission's commitment to support SMEs in its current FP7 program, as it enables us to participate in a high-profile research project that will generate fascinating new insights into epigenomics. It is of direct relevance to our business, as it will help us to offer our customers an even broader biological data background for their research. This will improve the understanding of molecular processes and hence lead to better biomedical applications."

 

Dr. Korbinian Grote, product manager at Genomatix, adds: "The BLUEPRINT epigenome project is a chance to work with high-quality epigenomics data from renowned institutions and labs from all over Europe. It will help us to further improve our existing line of next generation sequencing analysis products and will lead to the implementation of new ideas tailored towards the integration of epigenomic data into our interfaces and visualizations."

 

About BLUEPRINT:
In response to the call for a High Impact Initiative on the human epigenome, the BLUEPRINT consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by the International Human Epigenome Consortium (IHEC). The BLUEPRINT project has a total budget of almost 40 million euro and will receive 30 million euro funding from the EC-FP7-Cooperation-Health budget. The project started on October 1, 2011 and will run for 4.5 years. For further information, please visit http://www.blueprint-epigenome.eu/

 

About Genomatix:
Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (USA), Paris (France), London (UK) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.com

 

For further information please contact:

Genomatix
Dr. Martin Seifert
Email: seifert@genomatix.de
Phone: +49 89 599 766 0

 


 

Genomatix wins "Most Creative VIsualization" award at iDEA Challenge 2011.

Genomatix' solutions for NGS data analysis awarded in the commercial category at Illumina's San Diego iDEA conference.

 

Munich, Germany, August 23, 2011 - Genomatix has recently won the "Most Creative Visualization" award in the "commercial" category of Illumina's Data Excellence (iDEA) Challenge 2011, an achievement we are extremely proud of. iDEA is Illumina's program designed to challenge the scientific community to develop new and creative visualization and data analysis techniques.

 

"The iDEA challenge really sparked our interest from the very first moment we heard about it. Genomatix is a scientific company at heart, and we felt that getting our hands on a high quality, widely diverse dataset like the one Illumina provided for the Challenge would be an ideal test for our scientific approach to data analysis... which is to combine multiple lines of evidence to get from sequencing data to biological knowledge" says Dr. Jochen Supper, who presented Genomatix' submission at the San Diego iDEA meeting.

 

Dr. Martin Seifert, CEO of Genomatix, adds: "The Challenge was judged by a panel of renowned experts from the scientific community, and this is a great endorsement of the work we've done to date, as well as a significant motivation to push even harder in the future. Genomatix has always focused on providing intuitive interfaces and easy-to-understand visualizations. The combination of our scientifically validated algorithms and wealth of annotation data allows us to offer a comprehensive platform solution for Next Generation Sequencing data analysis. With the iDEA data being generated from cancer cell lines it also underlines the increasing relevance of our technologies for medical applications."

 

Additional coverage on the iDEA challenge can be found at Illumina's webpage (http://www.illumina.com/landing/idea/index.ilmn), Illumina's iCommunity newsletter (http://www.illumina.com/emailers/20110622_icommunity_june/iCommunity_june_2011_index_web.html) or the July/August issue of Bio-IT World magazine (http://www.bio-itworld.com). The finalists' presentations are available at http://www.illumina.com/landing/idea/conference/finalists.ilmn.


About Genomatix:

Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (U.S.A), Paris (France), London (U.K.) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.de or http://www.mygenomatix.com.

 


 

Genomatix Software, USU, and HJF Execute a CRADA: Prostate Cancer Prognostic Marker Discovery by Next Generation Sequencing

Cooperation to further progress in prostate disease research.


Munich, Germany, August 22, 2011 - Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation (HJF) for the Advancement of Military Medicine, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research. The aim of the joint research will be to differentiate patients with favorable versus poor prognosis at the time of diagnosis and primary treatment using definitive genetic markers. The majority of prostate cancer cases in PSA-screened population fall into a so called "grey zone" of prostate cancer where outcome is extremely difficult to predict at the time of diagnosis. The CRADA extends a long and already fruitful collaboration (Masuda, Werner et al, J Mol Biol. 353, 763-771 2005; Furusato et al, PCPD. 11, 194-97, 2008) with USU's Center for Prostrate Disease Research (CPDR). This collaboration combines CPDR's translational research resources and expertise and Genomatix' data analysis expertise in teasing out novel androgen receptor binding sites in the genome and analyzing prostate cancer metastasis using prostate cancer model systems and clinical specimens.

 

"This CRADA is a natural extension of accomplishments we have already achieved together," said Dr. Thomas Werner, founder of Genomatix Software. "Next Generation Sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring."

 

Dr. Shiv Srivastava; CPDR Co-director, Scientific Director, and Professor of Surgery at USU added: "Our work to date with Genomatix has been very productive. People from both our organizations have already established quality working relationships. Leveraging this and moving forward together into a technology as ground breaking as Next Generation Sequencing holds great promise for significant progress in prostate disease research."


About Genomatix:

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data analyses, our hardware and software solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis.


About CPDR:

The Center for Prostate Disease Research is an internationally recognized interdisciplinary program of the Uniformed Services University of the Health Sciences (USU). USU is the nation's federal health sciences university. USU students are primarily active-duty uniformed officers in the Army, Navy, Air Force and Public Health Service who are being educated to deal with wartime casualties, emerging infectious diseases and other public health emergencies. CPDR is affiliated with the Walter Reed Army Medical Center (WRAMC), several other military medical centers, and the Joint Pathology Center (part of the recently disestablished Armed Forces Institute of Pathology), and is operated in collaboration with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a non-profit foundation chartered to support USU and military medicine. The CPDR's mission of integrating basic science and clinical research to develop promising detection techniques and treatments for prostate cancer and associated diseases is fulfilled primarily through its three principal programs - the Clinical Research Program at WRAMC, the Basic Science Research Program at USU, and the Multicenter National Prostate Cancer Database.

 


 

mygenomatix: A Secure Cloud Like Model for NextGen Sequencing Data Analysis

Genomatix Launches Analysis Service: Affordable AND Powerful

 

Munich, Germany, March 15 2011 - The growing amount of data created by today's high throughput DNA sequencing technology presents a major challenge to scientists around the globe. How to handle the staggering amount of data, and, more importantly, how to answer the biological questions that initiated the experiment? Aside from the cost of the sequencing platforms themselves, significant amounts of money are being spent worldwide to expand hardware and storage resources, but getting to the biology requires access to data bases, analysis pipelines and other technologies to convert the data into biological knowledge... a daunting requirement for many users of Next Generation Sequencing (NGS).

 

Genomatix has established itself as a pioneer in the field of NGS data analysis, and has marketed a leading edge data analysis platform for intranet, in-house use for several years. However, the investment required for this platform is often beyond the means of the occasional user or even small core facility, confining the beneficiaries of this leading technology to larger sequencing core facilities and heavy users of the technology.

 

At the San Diego X-Gen conference and at the Human Genome Meeting in Dubai, Genomatix announces now a new service: mygenomatix.

With mygenomatix, Genomatix launches a service model that incorporates all the power of its in-house platform and combines it with the affordability of cloud computing and the security of an in-house solution... all at a very affordable price. mygenomatix will provide the user with:

  • Speed: receive your analyzed data back in a matter of one to two weeks.
  • Quality: users of mygenomatix will have access to the full Genomatix software and background data content as part of the service.
  • Results: biology matters, and Genomatix has excelled in providing meaningful biological analyses for over 13 years. Get biological results instead of endless columns of numbers.
  • Security: unlike standard cloud models, your data is always in a secure, protected environment.
  • Ease: Genomatix software has an excellent graphical user interface and standard operating procedures and workflows, with our excellent support team available to help if needed.
  • Accessibility: access to the Genomatix software and data content is provided via any standard internet browser from any internet-connected computer.
  • Affordability: contact Genomatix to find out how surprisingly affordable mygenomatix is.

mygenomatix will accept raw sequence or color space NGS data or, depending on your preference, aligned data to leverage Genomatix' extensive analysis capabilities and deep annotation.

 

"We are happy to announce the start of www.mygenomatix.com", says Dr. Martin Seifert (CEO of Genomatix). "We want to provide an easy entry to our excellent NGS data analysis and interpretation capabilities, complementing our turn-key in-house platforms, the Genomatix Mining Station (GMS) and the Genomatix Genome Analyzer (GGA). We have been exploring a cloud like model for quite some time, and our service model addresses the issue of security by getting the data to our computers via a hard disk shipment program. With mygenomatix, anyone doing NGS data analysis now has access to an easy entry path to our technology and databases." The service will be launched in April.

 

About Genomatix:

Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (U.S.A), Paris (France), London (U.K.) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.de or http://www.mygenomatix.com.